

Board of Governors of the Federal Reserve System, January 15, 2004.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 04-1291 Filed 1-21-04; 8:45 am]

BILLING CODE 6210-01-S

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 13, 2004.

**A. Federal Reserve Bank of Atlanta** (Sue Costello, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30303:

1. *CNB Holdings, Inc.*, Alpharetta, Georgia; to merge with First Capital Bancorp, Inc., Norcross, Georgia, and thereby indirectly acquire voting shares of First Capital Bank, Norcross, Georgia.

2. *Hometown Bancshares, Inc.*, Hamilton, Alabama; to become a bank holding company by acquiring 100 percent of the voting shares of PeoplesTrust Bank, Hamilton, Alabama.

Board of Governors of the Federal Reserve System, January 15, 2004.

**Robert deV. Frierson,**

*Deputy Secretary of the Board.*

[FR Doc. 04-1290 Filed 1-21-04; 8:45 am]

BILLING CODE 6210-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Vaccine Advisory Committee

**AGENCY:** Office of the Secretary.

**ACTION:** Notice of meeting.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (DHHS) is hereby giving notice that the National Vaccine Advisory Committee (NVAC) will hold a meeting. The meeting is open to the public.

**DATES:** The meeting will be held on February 3, 2004, from 9 a.m. to 5 p.m., and on February 4, 2004, from 8:30 a.m. to 3:15 p.m.

**ADDRESSES:** Department of Health and Human Services; Room 800 Humphrey Building; 200 Independence Avenue, SW.; Washington, DC 20201

**FOR FURTHER INFORMATION, CONTACT:** Ms. Carolin Commodore, Staff Assistant, National Vaccine Program Office and Executive Secretary, National Vaccine Advisory Committee; U.S. Department of Health and Human Services, Room 725H Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201; (202) 260-1253.

**SUPPLEMENTARY INFORMATION:** Pursuant to Section 2101 of the Public Service Act (42 U.S.C. Section 300aa-1), the Secretary of Health and Human Services was mandated to establish the National Vaccine Program (NVP) to achieve optimal prevention of human infectious diseases through immunization and to achieve optimal prevention against adverse reactions to vaccines. The Secretary designated the Assistant Secretary for Health to serve as the Director, NVP. The National Vaccine Advisory Committee (NVAC) was established to provide advice and make recommendations to the Director, NVP, on matters related to the program's responsibilities.

Topics to be discussed at the meeting include: Influenza, the smallpox vaccine program, poliovirus laboratory containment, an update on Project BioShield, vaccine supply, and NVPO unmet needs funds.

A tentative agenda will be made available for review on the NVPO Web site: <http://www.hhs.gov/nvpo>.

Public attendance at the meeting is limited to space available. Individuals

must provide a photo ID for entry into the Humphrey Building. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated contact person. Members of the public will have the opportunity to provide comments at the meeting. Public comment will be limited to five minutes per speaker. Any members of the public who wish to have printed material distributed to NVAC members should submit materials to the Executive Secretary, NVAC, whose contact information is listed above prior to close of business January 15, 2004. Pre-registration is required for both public attendance and comment. Any individual who wishes to attend the meeting and/or participate in the public comment session should call the telephone number listed in the contact information to register.

The National Vaccine Program Office was organizationally relocated to the Office of Public Health and Science on October 1, 2003.

Dated: January 2, 2004.

**Bruce Gellin,**

*Director, National Vaccine Program Office and Executive Secretary, National Vaccine Advisory Committee.*

[FR Doc. 04-1314 Filed 1-21-04; 8:45 am]

BILLING CODE 4150-28-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Neurological Indices of Long Term Solvent Exposure in Workers, Request for Applications OH-04-001

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

*Name:* Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Neurological Indices of Long Term Solvent Exposure in Workers, Request for Applications OH-04-001.

*Times and Dates:* 6 p.m.-6:30 p.m., February 11, 2004 (open); 6:30 p.m.-8 p.m., February 11, 2004 (closed); 9 a.m.-5 p.m., February 12, 2004 (closed); 9 a.m.-5 p.m., February 13, 2004 (closed).

*Place:* Embassy Suites Hotels, 1900 Diagonal Road, Alexandria, VA 22314, telephone 703-684-5900.

*Status:* Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Matters to be Discussed:* The meeting will include the review, discussion, and evaluation of applications received in response to Request for Applications: OH-04-001.

*Contact Person for More Information:* Pervis C. Major, Ph.D., Scientific Review Administrator, Office of Extramural Programs, National Institute for Occupational Safety and Health, CDC, 1095 Willowdale Road, Morgantown, WV 26505, telephone 304-285-5979.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the CDC and the Agency for Toxic Substances and Disease Registry.

Dated: January 14, 2004.

**Alvin Hall,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 04-1303 Filed 1-21-04; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Vaccines and Related Biological Products Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Vaccines and Related Biological Products Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on February 18, 2004, from 8:30

a.m. to 4:30 p.m.; and on February 19, 2004, from 8:30 a.m. to 12:30 p.m.

*Location:* The meeting will be held at the Sheraton Four-Points Hotel, 8400 Wisconsin Ave., Bethesda, MD.

*Contact Person:* William Freas or Denise H. Royster, Food and Drug Administration, Center for Biologics Evaluation and Research (CBER) (HFM-71), 1401 Rockville Pike, Rockville, MD 20852, 301-827-0314, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512391. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will review and discuss the selection of strains to be included in the influenza virus vaccine for the 2004-2005 season. The committee and CBER will begin a discussion of the potential suitability for use in vaccine manufacture of influenza isolates that have been passaged through mammalian cells (e.g., Madin-Darby Canine Kidney cells or Vero cells).

*Procedure:* On February 18 and 19, 2004, the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 4, 2004. Oral presentations from the public will be scheduled between approximately 1 p.m. to 1:30 p.m. on February 18, 2004, and between 8:45 a.m. to 9:15 a.m. on February 19, 2004. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 13, 2004, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact William Freas or Denise H. Royster at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: January 12, 2004.

**Peter J. Pitts,**

*Associate Commissioner for External Relations.*

[FR Doc. 04-1264 Filed 1-21-04; 8:45 am]

**BILLING CODE 4160-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Memorandum of Understanding Between the Food and Drug Administration and the Environmental Protection Agency, Office of Research and Development

[FDA 225-04-4000]

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the U.S. Environmental Protection Agency (EPA), Office of Research and Development. The purpose of the MOU is to expedite research and development of new methods and technologies that can be implemented in support of Homeland Security efforts by Federal, State or local government entities as well as authorized private sector organizations to avert and/or mitigate the effects of terrorist activities in the United States.

**DATES:** The agreement became effective February 19, 2003.

**FOR FURTHER INFORMATION CONTACT:**

Frederick L. Fricke, Jr., Forensic Chemistry Center (HFR-CE500), Food and Drug Administration, 6751 Steger Dr., Cincinnati, OH 45237, 513-679-2700, ext. 180.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the **Federal Register**, the agency is publishing notice of this MOU.

Dated: January 9, 2004.

**Jeffrey Shuren,**

*Assistant Commissioner for Policy.*

**BILLING CODE 4160-01-S**